Alnylam Pharmaceuticals | ALNY - Current Assets


Alnylam Pharmaceuticals reported $4.62B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amgen USD 31.48B 2.42B Mar/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Moderna USD 5.82B 45M Jun/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novartis USD 26.61B 3.85B Mar/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.16B 789M Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Takeda JPY 3.15T 59.77B Jun/2026
Tectonic Therapeutic USD 239.89M 17.47M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026
Xencor USD 482.85M 116.97M Mar/2026